Designer vaccines for parasitic diseases

被引:23
|
作者
Cox, FEG
机构
关键词
parasitic infections; vaccines; cytokines; T-cell subsets; Th1; responses; Th2; interferon-gamma; Leishmania major; Salmonella typhimurium;
D O I
10.1016/S0020-7519(97)00112-4
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Conventional ways of developing vaccines against infections, either on pragmatic grounds or by identifying protective antigens and attempting to mimic natural immune responses, have largely been unsuccessful for parasitic infections, mainly because of the complexity of the immunological processes involved, It is clear that a new approach is required and it is now known that the ''immunological environment'' in which the immune response is initiated is as, or more, important than the actual antigens used. CD4+ and CD8+ T1 cells, through the agency of IL-2 and IFN-gamma, direct the response towards cell-mediated immunity involving cytotoxicity and macrophage activation, whereas T2 cells, through the agency of IL-4 and IL-10, direct the response towards antibody production. The two poles are counter-regulatory in that IFN-gamma inhibits antibody formation and IL-4 and IL-10 inhibit macrophage activation. However, immune responses are not immutable and can be artificially driven towards one or other pole, for example IFN-gamma, IL-2 and IL-12 favour T1 responses, whereas IL-4 and IL-10 favour the T2 type. With this knowledge, it is possible to design recombinant or nucleic acid vaccines that include gene products or genes for desirable cytokines as well as the appropriate antigen. For example, in experimental leishmaniasis, protective immune responses can be induced by the incorporation of genes for IL-2 and IFN-gamma, into recombinant Salmonella typhimurium vectors and nucleic acid vaccines. A similar approach might be appropriate in experimental schistosomiasis, in which exogenous IL-12 drives the immune response towards the T1 pole and ameliorates T2-mediated pathology. These approaches require novel delivery systems and these have already begun to produce encouraging results. However, simply modifying the nature and route of administration of the vaccine is not enough and attention has now turned to the effector molecules involved, for example nitric oxide, and the signalling systems that are modified by the presence of particular cytokines. (C) 1997 Australian Society for Parasitology. Published by Elsevier Science Ltd.
引用
收藏
页码:1147 / 1157
页数:11
相关论文
共 50 条
  • [1] VACCINES FOR PARASITIC DISEASES
    HIGASHI, GI
    [J]. ANNUAL REVIEW OF PUBLIC HEALTH, 1988, 9 : 483 - 501
  • [2] VACCINES AGAINST PARASITIC DISEASES
    EAST, IJ
    GOODGER, BV
    WILLADSEN, P
    WRIGHT, IG
    [J]. SCIENCE, 1985, 227 (4688) : 704 - 704
  • [3] Vaccines against parasitic diseases
    Harber, Lisa
    [J]. VETERINARY RECORD, 2014, 175 (08)
  • [4] Vaccines for parasitic and bacterial diseases
    Reed, SG
    Campos-Neto, A
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2003, 15 (04) : 456 - 460
  • [5] Role of parasitic vaccines in integrated control of parasitic diseases in livestock
    Sharma, Neelu
    Singh, Veer
    Shyma, K. P.
    [J]. VETERINARY WORLD, 2015, 8 (05) : 590 - 598
  • [6] PROGRESS IN THE DEVELOPMENT OF VACCINES AGAINST PARASITIC DISEASES
    GAMBLE, HR
    MURRELL, KD
    [J]. IMMUNOLOGY LETTERS, 1987, 16 (3-4) : 329 - 336
  • [7] DNA vaccines against tropical parasitic diseases
    Da'dara, AA
    Harn, DA
    [J]. EXPERT REVIEW OF VACCINES, 2005, 4 (04) : 575 - 589
  • [8] Vaccines against human parasitic diseases: an overview
    Abath, FGC
    Montenegro, SML
    Gomes, YM
    [J]. ACTA TROPICA, 1998, 71 (03) : 237 - 254
  • [9] New vaccines for neglected parasitic diseases and dengue
    Beaumier, Coreen M.
    Gillespie, Portia M.
    Hotez, Peter J.
    Bottazzi, Maria Elena
    [J]. TRANSLATIONAL RESEARCH, 2013, 162 (03) : 144 - 155
  • [10] DNA vaccines: a rational design against parasitic diseases
    Carvalho, Joana A.
    Rodgers, Jean
    Atouguia, Jorge
    Prazeres, Duarte M. F.
    Monteiro, Gabriel A.
    [J]. EXPERT REVIEW OF VACCINES, 2010, 9 (02) : 175 - 191